• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form PX14A6G filed by Assertio Holdings Inc.

    5/14/24 5:22:39 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASRT alert in real time by email
    PX14A6G 1 p24-1812px14a6g.htm ASSERTIO HOLDINGS, INC.

    U.S. Securities and Exchange Commission
    Washington, DC 20549

     

    NOTICE OF EXEMPT SOLICITATION

     

     

     

    1. Name of the Registrant:

     

    Assertio Holdings, Inc.

     

    2. Name of persons relying on exemption:

     

    Buxton Helmsley Group, Inc.

     

    3. Address of persons relying on exemption:

     

    1185 Avenue of the Americas, Floor 3, New York, NY 10036-2600

     

    4. Written materials: The attached written materials are submitted pursuant to Rule 14a-6(g)(1) (the “Rule”) promulgated under the Securities Exchange Act of 1934, in connection with a proposal to be voted on at the Registrant’s 2024 Annual Meeting. Submission is not required of this filer under the terms of the Rule but is made voluntarily by the proponent in the interest of public disclosure and consideration of these important issues.

     

    BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE "AGAINST" DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS

    NEW YORK, May 13, 2024 /PRNewswire/ -- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fund manager that holds a significant interest in the common stock shares of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) urges Assertio stockholders to vote "against" all of the Company's director nominees at the Company's upcoming 2024 annual meeting of stockholders on May 23, 2024 (the "Annual Meeting"). BHG strongly believes that significant change to the Assertio board of directors (the "Board") is necessary in order to bring about new oversight and reinstate stockholder-like judgment in the Boardroom. Any stockholders who have already cast their ballots should immediately call their broker to change their ballot to reflect a vote "against" all Assertio directors.

    In addition, Assertio stockholders are urged to communicate their support of BHG's campaign and opposition to the present Assertio Board via a news release or private letter to the Board. Letters to the Board may be sent to [email protected], with a copy to BHG at [email protected].

     

    Alexander Parker, Senior Managing Director at BHG, explained the rationale for the campaign:

    "Assertio is a valuable company that fulfills very critical needs in the healthcare system. That said, after alarming communications between us and Assertio's Board and management, we have concluded that Assertio's Board requires change to reinstate stockholder-like judgment in the Boardroom and restore value for all stockholders. It is abundantly clear to us that without meaningful change, stockholders likely face imminent irreparable harm. 

    "We have made numerous attempts to avoid aggressive public action, but it seems more and more clear to us that this incumbent Board requires outside pressure to change. To that end, we recently privately proposed that the Board appoint two new directors, which the Company and Board appears to have rejected. Such a rejection makes it very clear that this Board just wants to retain control. It's no wonder they have driven out the last apparent remaining director (James Tyree) who was able to recognize the Board's inappropriate decision-making, who was willing to put his foot down, and who now has resigned in protest.1

    "If the Board simply accepts our proposal to add directors (who will serve without cash compensation), it can avoid a costly proxy contest with BHG that would cost stockholders hundreds of thousands of dollars, if not millions.

    "Developments under the current regime are disturbing. Under the leadership of Chairman Peter Staple, Assertio acquired Spectrum Pharmaceuticals in Q3 2023, yet admitted—within a mere quarter's time—to have overpaid by approximately 75%, or $150 million. This resulted in legacy Assertio stockholder interests being diluted four times as much as necessary (effectively handing a substantial portion of the legacy Assertio business to Spectrum's pre-acquisition stockholders at no cost to them).

    "This Board has made clear it is both incapable of sufficient oversight of management and that it does not hold itself accountable for massive blunders like the Spectrum acquisition. Nor does it seem to be incentivized to since there's a tension created between pursuing a financial recovery over misrepresentations in the Spectrum acquisition catastrophe and what we can only imagine is the Board's desire to save face after clearly failing to conduct adequate due diligence and forethought leading up to the Spectrum acquisition. This Board has a clear conflict of interest in that pursuing recovery for the Spectrum blunder that occurred under its oversight, would likely be perceived by most investors as failures of this Board to engage in due diligence. The only directors who would not be exposed to that conflict of interest would be new, shareholder-appointed directors, and that is precisely what BHG is pursuing and has proposed."

    "While the Board has just taken action by ousting some of Assertio's top executives, not a single non-executive director has held themselves accountable by tendering a resignation. Even Mr. Staple—who has ultimate responsibility for oversight of the Board as Chairman—continues to serve in his role. Mr. Staple was due to resign this year after nearly two decades on the Board and upon reaching Assertio's mandatory retirement age, yet the Board outrageously granted him the preferential treatment of a waiver to remain serving as a director. As a result of this, James Tyree resigned in protest and the Company announced he would not stand for re-election at the Annual Meeting."2

    "When BHG inquired about the due diligence failures in the Spectrum acquisition, the Assertio Board and management's responses were beyond alarming. The Company refused to give a reliable written response over critical, material matters that should have already been disclosed in SEC filings – in certain cases also implicating that the response to the questions would indeed be material. In a meeting with BHG on May 7, 2024, certain members of Assertio's Board and management gave materially different responses than what they put in writing before the meeting, when BHG had already forewarned any material explanation needed to be in writing due to the criticality of the matters and to ensure a genuine, reliable answer was being given. The Board and management then resorted to defending their existing public disclosures. We now see that Assertio's Board and management are apparently fine with minimal, inadequate disclosure, which represents a danger of imminent irreparable harm to Assertio's public investors who rely on such woefully deficient disclosures."

    "It is not possible for investors to effectively value Assertio securities without the information BHG has sought. BHG believes this undisclosed information may be the reason behind why none of Assertio's directors have purchased a single share of stock with their own funds in the past three years. We also believe the Company's stock would likely not be trading at such depressed levels if the Board would disclose certain information implicated to be materially positive. The Board and management of Assertio outrageously questioned BHG why it was obligated to disclose positive financial information that it is withholding, effectively suppressing Assertio's stock price. That information, if material as the Company implicated it to be, was already required to be disclosed to public market participants pursuant to Regulation S-X."

    BHG, with a track record of relentless investor advocacy, has demanded two seats on the Assertio Board to provide currently lacking oversight in the areas of disclosure, due diligence, capital allocation strategy, and otherwise. 

    BHG also believes that Assertio's Board should initiate a modest, but material share repurchase program (to take some level of action for defense against the Company's valuation, and to capitalize on the Company's depressed stock price for the benefit of long-term stockholders), and also wishes to restore stockholder-like judgment in the boardroom in relation to expenses. For instance, the Board has spent hundreds of thousands of dollars on paid analyst coverage—which even this Board and management could not justify as to how that creates long-term stockholder value—and, though the Board could not justify the expense, they regarded this corporate waste as being acceptable to continue because it is "immaterial." BHG does not regard hundreds of thousands of dollars as 'immaterial' at Assertio (especially, when Assertio's equity market capitalization is approximately $94 million), and knows that investors would rather see these funds allocated toward share repurchases. We believe the Board's cluelessness regarding the effects of its decisions on investors is likely due to its low ownership stake in Assertio.

    Mr. Parker concluded, "This Board clearly spends 'other people's money' – including in connection with acquisitions and unjustified expenses – with no regard. Stockholders need to immediately correct this problem by installing directors who will serve as fiduciaries committed to conserving and maximizing value. The current Board is failing miserably in this regard."

    BHG intends to provide additional detail regarding these matters in the time leading up to the Annual Meeting. Unless the Board accepts BHG's proposal, BHG will likely initiate a solicitation as a referendum on the Board. BHG's current proposal involves:

    ·The Addition of Two New Directors:
    1.Director #1: Alexander E. Parker – Mr. Parker serves as Senior Managing Director of Buxton Helmsley, overseeing the firm's investor advocacy efforts. Through a number of investor advocacy campaigns, he is known for utilizing his straightforward business acumen, in combination with his extensive knowledge of accounting and legal obligations at publicly traded entities, to both maximize and protect the financial interests of the investors whose interests he is entrusted to represent. Mr. Parker's track record of above-average due diligence capability, having uncovered even repeat accounting and securities fraud schemes at public companies, has led to his insight being requested as part of regulatory investigations and his allegations being pursued via class-action investor litigation.
       
      Most recently, Mr. Parker secured independent board representation at Fossil Group, Inc. after receiving answers to due diligence questioning that presented an apparent risk to investors.
       
      BHG's proposal involves Mr. Parker agreeing to accept all-equity compensation, and to then share his expertise, extensive experience, and track record of stockholder advocacy for the benefit of all Assertio stockholders. BHG notes that no other Assertio director has accepted such zero cash compensation. BHG believes Mr. Parker's presence on the Board will both dissuade further inappropriate Board conduct and also foster an environment of directors not simply accepting inappropriate actions, such as the inappropriate herd behavior that led to director James Tyree resigning in protest.

    2.Director #2 – BHG has delivered a list of six (6) highly qualified candidates to serve as the second new director, leaving the choice to the Board. These candidates have varying backgrounds and experience, primarily relating to capital markets, capital allocation strategy, regulatory compliance, and financial reporting. Thus far, the Board has not advised BHG that it is unable to find a suitable candidate on this list.

     

    ·One Director Stepping Down: One Assertio director must step down, both to eliminate stale knowledge in the Boardroom and to avoid an even-sized Board that could lead to gridlock. As it stands, Assertio's current six-person, even-numbered Board leaves dangerous room for gridlock in deciding critical matters and is yet another example of poor corporate governance.

    BHG urges Assertio stockholders to immediately cast votes "against" all of Assertio director nominees at the upcoming May 23, 2024 Annual Meeting. If a stockholder has already cast their ballot, they should immediately call their broker to change their ballot to reflect a vote "against" all Assertio directors.

    THE FOREGOING INFORMATION MAY ALSO BE DISSEMINATED TO STOCKHOLDERS VIA TELEPHONE, AND EMAIL AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE OR AS A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. THE COST OF DISSEMINATING THE FOREGOING INFORMATION TO STOCKHOLDERS IS BEING BORNE ENTIRELY BY BHG. PROXY CARDS WILL NOT BE ACCEPTED BY BHG. PLEASE DO NOT SEND YOUR PROXY TO BHG. TO VOTE YOUR PROXY, PLEASE FOLLOW THE INSTRUCTIONS ON YOUR PROXY CARD SENT TO YOU BY ASSERTIO.

    About Buxton Helmsley

    The Buxton Helmsley Group, Inc. is a New York City-based investment advisory firm and fund manager, engaging both active and passive investment strategies across a range of asset classes, with a general focus on opportunities in North America and Europe. The investment approach is based on deep fundamental analysis and risk management, with a focus on ensuring disclosure obligations are being upheld under applicable accounting standards and securities laws.

    Media Contact:
    Public Relations and Corp. Comm.
    Tel: +1 (212) 561 - 5540, Option 4
    [email protected]

    Cautionary Statement Regarding Forward-Looking Statements

    This press release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein in any state to any person. The information herein contains "forward-looking statements". Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "potential," "targets," "forecasts," "seeks,""could," "should" or the negative of such terms or other variations on such terms or comparable terminology. Similarly,statements that describe our objectives, plans or goals are forward-looking. Forward-looking statements are subject to various risks and uncertainties and assumptions. There can be no assurance that any idea or assumption herein is, or will be proven, correct or that any of the objectives, plans or goals stated herein will ultimately be undertaken or achieved. If one or more of such risks or uncertainties materialize, or if BHG's underlying assumptions prove to be incorrect, the actual results may vary materially from outcomes indicated by these statements. Accordingly, forward-looking statements should not be regarded as a representation by BHG that the future plans, estimates or expectations contemplated will ever be achieved.

    1 See Form 8-K, filed by the Company on April 2, 2024.
    2 See Form 8-K, filed by the Company on April 2, 2024.

    SOURCE Buxton Helmsley Group, Inc.

     

    Get the next $ASRT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASRT

    DatePrice TargetRatingAnalyst
    7/26/2024$3.00Buy
    Maxim Group
    7/3/2024$4.00Buy
    H.C. Wainwright
    11/7/2022$7.00Buy
    Lake Street
    More analyst ratings

    $ASRT
    SEC Filings

    View All

    Assertio Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - Assertio Holdings, Inc. (0001808665) (Filer)

    1/12/26 4:44:05 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Assertio Holdings, Inc. (0001808665) (Filer)

    12/22/25 4:37:55 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Assertio Holdings Inc.

    8-K - Assertio Holdings, Inc. (0001808665) (Filer)

    11/21/25 5:00:38 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements

    Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with all applicable listing requirements. As of January 12, 2026, Nasdaq has determined that Assertio has regained compliance with the Minimum Bid Price Rule, which requires the Company's common stock maintains a minimum bid price of $1.00 per share for a minimum of ten consecutive days, and that the matter is now closed. Mark Reisenauer, Chief Executive Officer of Assertio: "We are pleased to have regained compliance with applicable listing requirements. Importantly, we accomplished thi

    1/12/26 4:15:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

    Peer-reviewed publication in "The Oncologist" is now available online Investigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day dosing Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an effective neutrophil recovery an

    1/9/26 1:45:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

    Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the "Certificate of Amendment") on December 19 to implement a one-for-fifteen reverse split of its issued and outstanding common stock (the "Reverse Split"). The Reverse Split will become effective as of 12:01 a.m. Eastern Time on December 26, 2025, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on December 26, 2025. The Company's common stock will continue to trade on The Nasdaq Stock Market LLC ("Nasdaq") under the symbol "ASRT." The new CUSIP number for the common stock follow

    12/22/25 4:30:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Assertio Therapeutics with a new price target

    Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00

    7/26/24 7:49:44 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Assertio Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $4.00

    7/3/24 7:25:55 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Assertio Therapeutics with a new price target

    Lake Street initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $7.00

    11/7/22 9:24:08 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/19/24 9:02:18 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/15/24 2:43:25 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/12/24 6:00:09 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO Reisenauer Mark L

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/14/25 6:00:11 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Stark David Matthew sold $6,806 worth of shares (8,959 units at $0.76), decreasing direct ownership by 8% to 98,541 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/12/25 6:00:15 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO O'Grady Brendan P. converted options into 166,665 shares and covered exercise/tax liability with 49,416 shares, increasing direct ownership by 1,002% to 128,955 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/3/25 6:00:13 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Financials

    Live finance-specific insights

    View All

    Assertio Announces Leadership Transition

    Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that its Board of Directors (the "Board") has appointed director Mark L. Reisenauer as the Company's Chief Executive Officer ("CEO"), effective immediately. As part of this transition, current CEO Brendan P. O'Grady will be departing the Company. Heather L. Mason, Chair of the Board of Directors, stated, "After significant del

    10/28/25 9:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025

    LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release second quarter 2025 financial results on Monday, August 11, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide business updates on the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcas

    8/5/25 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

    LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim

    5/5/25 8:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Leadership Updates

    Live Leadership Updates

    View All

    Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

    LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. "Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board," said Heather Mason, Chair of Assertio. "His successful new product and indication launches have b

    12/17/24 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

    LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company's Chief Commercial Officer and was previously CFO. "As CTO, Paul will be future looking, working closely with me, to identify synergies, innovative strategies, and new revenue streams to best position the company for future growth," said Brendan O'Grady, Chief Executi

    12/12/24 8:00:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

    CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

    12/6/24 7:00:00 AM ET
    $ASRT
    $BEAM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ASRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/14/24 3:52:50 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/12/24 1:34:28 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/4/24 11:29:13 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care